Glucagon-like peptide (GLP)-1 receptor agonists enhance insulin secretion and may improve pancreatic islet cell function. However, GLP-1 receptor (GLP-1R) agonist treatment may have more complex, and sometimes deleterious, effects on beta cells. We discuss the concepts of beta cell protection versus exhaustion for different GLP-1R agonists based on recent data
Background: Agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucokinase activators (GKA) a...
Chronic exposure of pancreatic beta-cells to saturated free fatty acids (FFAs) causes endoplasmic re...
Glucagon-like peptide-1 (GLP-1)-based therapy of type 2 diabetes is executed either by GLP-1 recepto...
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs...
Glucagon-like peptide-1 (GLP-1) is a potent gluco-incretin hormone, which plays a central role on pa...
<div><p>Glucagon-like peptide-1 (GLP-1) is a potent gluco-incretin hormone, which plays a central ro...
AIMS/HYPOTHESIS: Incretin-based therapies improve glycaemic control in patients with type 2 diabetes...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, stimulates insulin secretion f...
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used...
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from vario...
Aim Earlier studies have shown that peptide glucagon-like peptide-1 receptor (GLP-1R) agonists with ...
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 d...
Islet dysfunction - characterized by a combination of defective insulin secretion, inappropriately h...
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the tre...
Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM...
Background: Agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucokinase activators (GKA) a...
Chronic exposure of pancreatic beta-cells to saturated free fatty acids (FFAs) causes endoplasmic re...
Glucagon-like peptide-1 (GLP-1)-based therapy of type 2 diabetes is executed either by GLP-1 recepto...
Glucagon like peptide-1 (GLP-1) is an incretin secretory molecule. GLP-1 receptor agonists (GLP-1RAs...
Glucagon-like peptide-1 (GLP-1) is a potent gluco-incretin hormone, which plays a central role on pa...
<div><p>Glucagon-like peptide-1 (GLP-1) is a potent gluco-incretin hormone, which plays a central ro...
AIMS/HYPOTHESIS: Incretin-based therapies improve glycaemic control in patients with type 2 diabetes...
Introduction: Glucagon-like peptide-1 (GLP-1) is produced by the gut, stimulates insulin secretion f...
Today, glucagon-like peptide-1 (GLP-1) receptor agonists are established glucose-lowering drugs used...
The prevalence of type 2 diabetes (T2D) is increasing worldwide. Patients with T2D suffer from vario...
Aim Earlier studies have shown that peptide glucagon-like peptide-1 receptor (GLP-1R) agonists with ...
A relatively recent addition to the arsenal of antidiabetic drugs used for the treatment of type 2 d...
Islet dysfunction - characterized by a combination of defective insulin secretion, inappropriately h...
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the tre...
Loss or dysfunction of the pancreatic beta cells or insulin receptors leads to diabetes mellitus (DM...
Background: Agonists of glucagon-like peptide-1 receptor (GLP-1R) and glucokinase activators (GKA) a...
Chronic exposure of pancreatic beta-cells to saturated free fatty acids (FFAs) causes endoplasmic re...
Glucagon-like peptide-1 (GLP-1)-based therapy of type 2 diabetes is executed either by GLP-1 recepto...
DOI
Add to ORKG